Dynavax Technologies (NASDAQ:DVAX) Rating Lowered to Hold at StockNews.com

StockNews.com lowered shares of Dynavax Technologies (NASDAQ:DVAX) from a buy rating to a hold rating in a research note published on Friday.

Several other research analysts have also recently weighed in on DVAX. The Goldman Sachs Group started coverage on Dynavax Technologies in a research note on Thursday, February 1st. They issued a neutral rating and a $20.00 price target for the company. William Blair reissued an outperform rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Dynavax Technologies has an average rating of Moderate Buy and an average price target of $25.00.

Dynavax Technologies Stock Up 1.2 %

Shares of Dynavax Technologies stock opened at $11.34 on Friday. The company has a 50-day simple moving average of $12.20 and a two-hundred day simple moving average of $13.15. Dynavax Technologies has a 52-week low of $10.06 and a 52-week high of $15.15. The company has a debt-to-equity ratio of 0.41, a quick ratio of 12.96 and a current ratio of 13.81. The stock has a market capitalization of $1.48 billion, a PE ratio of -188.97 and a beta of 1.26.

Insiders Place Their Bets

In other news, CAO Justin Burgess sold 20,526 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.98% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dynavax Technologies

A number of large investors have recently made changes to their positions in DVAX. AE Wealth Management LLC purchased a new position in shares of Dynavax Technologies in the third quarter worth approximately $527,000. SG Americas Securities LLC bought a new stake in shares of Dynavax Technologies during the 3rd quarter valued at $1,112,000. State of Alaska Department of Revenue increased its stake in shares of Dynavax Technologies by 1.4% in the 3rd quarter. State of Alaska Department of Revenue now owns 79,735 shares of the biopharmaceutical company’s stock worth $1,177,000 after purchasing an additional 1,111 shares in the last quarter. Peregrine Capital Management LLC raised its holdings in Dynavax Technologies by 10.2% in the 3rd quarter. Peregrine Capital Management LLC now owns 618,250 shares of the biopharmaceutical company’s stock worth $9,132,000 after purchasing an additional 57,342 shares during the period. Finally, Maryland State Retirement & Pension System lifted its position in Dynavax Technologies by 1.9% during the third quarter. Maryland State Retirement & Pension System now owns 47,440 shares of the biopharmaceutical company’s stock valued at $701,000 after purchasing an additional 885 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.